Combination chemotherapy for relapsed small-cell lung cancer
-
Published:2016-08
Issue:8
Volume:17
Page:1033-1035
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Author:
Kalemkerian Gregory P
Reference10 articles.
1. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer;O'Brien;J Clin Oncol,2006
2. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;Von Pawel;J Clin Oncol,1999
3. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer;Owonikoko;J Thorac Oncol,2012
4. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial;Goto;Lancet Oncol,2016
5. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer;Goto;Br J Cancer,2004
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献